Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 10;12:211–219. doi: 10.2147/IDR.S188538

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Lan et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Drug resistance patterns.

Notes: Sixty-six MDR-, pre-XDR- and XDR-TB clinical isolates were tested for drug susceptibility against four first-line (rifampicin, isoniazid, streptomycin and ethambutol) and six second-line (gatifloxacin, levofloxacin, moxifloxacin, amikacin, capreomycin and kanamycin) anti-TB drugs. The heterogeneity in drug resistance patterns of MDR-TB isolates is displayed as a percentage of isolates resistant to a different number of anti-TB drugs.

Abbreviations: MDR-TB, multidrug-resistant TB; TB, tuberculosis; XDR-TB, extensively drug resistant TB.